We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Managing diabetes in diabetic patients with COVID: where do we start from?
- Authors
Avogaro, Angelo; Bonora, Benedetta; Fadini, Gian Paolo
- Abstract
Aims: COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality. Methods: We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 to March 31st, 2021. We excluded editorials, commentary, letters to the editor, reviews, and studies that did not have mortality as an outcome. For metformin and insulin only, we performed a meta-analysis using Cochrane RevMan 5.2. Results: Among antidiabetic drugs, metformin was the only drug associated with a reduced risk of mortality. Conversely, insulin appears associated with an increased risk. The other classes of drugs were neutral. Conclusions: The totality of articles reports retrospective data strongly affected by "channeling bias" so that most of the existing results on each class of drugs are driven by the phenotype of patients likely to receive that specific drug by prescription.
- Subjects
COVID-19; PEOPLE with diabetes; METFORMIN; HYPOGLYCEMIC agents; DRUGS; DRUG prescribing; MEDICAL prescriptions
- Publication
Acta Diabetologica, 2021, Vol 58, Issue 11, p1441
- ISSN
0940-5429
- Publication type
Article
- DOI
10.1007/s00592-021-01739-1